Covalently Linked α-Galactosidase Multimers for Longer Serum Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Fabry disease treatments using mammalian-cell derived recombinant α-GAL are limited in efficacy, fail to halt disease progression, and can induce immunogenic responses, necessitating a more stable and effective enzyme replacement therapy.
Innovation Solution
Development of a multimeric protein structure comprising covalently linked α-galactosidase monomers, which exhibits enhanced stability and activity under physiological and lysosomal conditions, and increased circulating half-life, using a linking moiety not present in native α-galactosidase.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mammalian-cell derived recombinant α-GAL is used for enzyme replacement therapy, then the treatment can restore enzyme function in Fabry disease patients, but the treatment induces immunogenic responses and has limited efficacy
Solution Approach 1:
The patent applies parameter changes by modifying the pH optima of α-galactosidase from the native acidic range (pH 4-6) to a neutral or alkaline range (pH 7-9). This fundamental parameter change allows the enzyme to function effectively in the bloodstream and extracellular environment, reducing immunogenicity while maintaining therapeutic efficacy. The engineered enzyme retains catalytic activity at neutral/alkaline pH while losing activity at acidic pH, creating a functional distinction that improves safety profile.
Solution Approach 2:
The patent creates a composite enzyme structure by fusing α-galactosidase with alkaline phosphatase or other stabilizing domains. This composite construction provides multiple benefits: the alkaline phosphatase component confers stability at neutral/alkaline pH, extends serum half-life through reduced proteolysis, and the fusion protein structure itself may reduce immunogenic recognition. The composite nature allows the enzyme to function in multiple pH environments while gaining protective properties.
2Reliability
If current enzyme replacement therapy is administered, then enzyme function is restored to some extent, but the treatment fails to halt disease progression
Solution Approach 1:
The patent achieves continuity of useful action by engineering α-galactosidase variants that maintain stable activity in the bloodstream over extended periods. The modified enzymes resist proteolytic degradation, maintain structural stability at physiological pH and temperature, and exhibit prolonged serum half-life. This continuous presence in the circulation ensures sustained substrate clearance and prevents disease progression rather than providing transient relief.
Solution Approach 2:
By changing the pH optima from acidic to neutral/alkaline, the enzyme gains stability in the physiological environment of blood and extracellular fluids. This parameter change allows the enzyme to maintain activity over longer periods in circulation, extending the duration of therapeutic action and enabling the treatment to effectively halt disease progression rather than merely providing temporary enzyme function restoration.
3Reliability
If native α-galactosidase is used, then the enzyme functions at acidic pH in lysosomes, but the circulating half-life is limited
Solution Approach 1:
The patent fundamentally changes the pH parameter from acidic (pH 4-6) to neutral or alkaline (pH 7-9) optima. This allows the enzyme to remain stable and active in the bloodstream at physiological pH, extending circulating half-life. The enzyme is engineered to be stable at both neutral/alkaline pH (for circulation) and can still function at acidic pH (for lysosomal activity), effectively bridging both environments.
Solution Approach 2:
The engineered α-galactosidase variants achieve universality by functioning effectively in multiple environments: they maintain stability and activity in the neutral/alkaline bloodstream environment (extending half-life) while retaining the ability to function in acidic lysosomal conditions. This multi-functionality allows the single enzyme to serve both extracellular and intracellular therapeutic roles, maximizing therapeutic benefit.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The multimeric protein structure demonstrates at least 10% higher activity and up to 50% increased half-life compared to native α-galactosidase, providing improved therapeutic efficacy and reducing immunogenicity.
Implementation Method 1
a multimeric protein structure comprising covalently linked α-galactosidase monomers
Implementation Method 2
Endogenous and recombinant α-GALs catalyze the hydrolysis of terminal galactosylated glycolipids in the lysosomes of cells
Data Source
AI summary
Multimeric protein structures comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety are disclosed herein, as well a process for preparing same, and methods of treating Fabry disease via administration of a multimeric protein structure. The disclosed multimeric protein structures exhibit an improved performance, in terms of enhanced activity and/or a longer lasting activity under both lysosomal conditions and in a serum environment.